Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Jürgen Kuball, MD, PhD, Utrecht University, Utrecht, The Netherlands, briefly comments on the promise of novel off-the-shelf CAR-T products and where these may fit in the treatment of hematological malignancies. This interview took place at the EBMT-EHA 5th European CAR T-cell Meeting held in Rotterdam, The Netherlands.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Dr. Kuball reports grants from Gadeta, Novartis, and Miltenyi Biotech, and is the inventor on patents dealing with γδT cell-related aspects, as well as the co-founder and shareholder of Gadeta.